LONDON (Alliance News) - The following shares received analyst recommendations Friday morning and Thursday:
----------
FTSE 100
----------
MORGAN STANLEY CUTS GLAXOSMITHKLINE PRICE TARGET TO 1600 (1800) PENCE
----------
MORGAN STANLEY CUTS GLAXOSMITHKLINE TO 'EQUAL-WEIGHT' ('OVERWEIGHT')
----------
HSBC STARTS AB FOODS WITH 'BUY' - PRICE TARGET 3680 PENCE
----------
JPMORGAN RAISES BAE SYSTEMS PRICE TARGET TO 445 (410) PENCE - 'UNDERWEIGHT'
----------
HSBC RAISES LLOYDS TO 'BUY' ('HOLD') - TARGET 103 (87) PENCE
----------
DEUTSCHE BANK CUTS TESCO PRICE TARGET TO 240 (275) PENCE - 'BUY'
----------
DEUTSCHE BANK CUTS MORRISON PRICE TARGET TO 180 (210) PENCE - 'HOLD'
----------
FTSE 250
----------
JEFFERIES RAISES ESSENTRA PRICE TARGET TO 1125 (1090) PENCE - 'BUY'
----------
PANMURE RAISES HANSARD GLOBAL PRICE TARGET TO 113 (105) PENCE - 'BUY'
----------
Investec Ups Halfords Price Target To 560p From 545p, Keeps At Buy
----------
NOMURA CUTS PETS AT HOME PRICE TARGET TO 245 (295) PENCE - 'BUY
----------
TRADERS: NUMIS CUTS BETFAIR TO 'SELL' ('REDUCE')
----------
LIBERUM RAISES PAYPOINT PRICE TARGET TO 1100 (900) PENCE - 'HOLD'
----------
MAIN MARKET AND AIM
----------
WH Ireland Sets UK Oil & Gas Investments Target Price At 5p After Review
----------
WH Ireland Moves UK Oil & Gas Investments To Buy From Under Review
----------
JPMORGAN RAISES WINCANTON PRICE TARGET TO 211 (201) PENCE - 'OVERWEIGHT'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun
Copyright 2015 Alliance News Limited. All Rights Reserved.
GSK's depemokimab asthma treatment meets endpoints in latest trials
(Alliance News) - GSK PLC on Tuesday announced positive results from trials of depemokimab, an "ultra-long-acting biologic" that could simplify treatment options for patients with severe asthma.
Read more